Bruker Announces Acquisition of biocrates
The acquisition further enhances Bruker’s MS-based metabolomics solutions
Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.
biocrates is a leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform combines innovative sample preparation, metabolite identification, and data analysis.
The acquisition of biocrates further enhances Bruker’s MS-based metabolomics solutions. It also supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software, and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys.
Dr. Oliver Rinner, Bruker’s Vice President for Enabling Multiomics Solutions and founder and CEO of Biognosys stated: “Multiomics is the cornerstone for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. With our services, software and kits for high-end proteomics and metabolomics we can now support customers with a truly integrated multiomics approach.”
"Our acquisition of biocrates represents a pivotal step in our ambitious metabolomics and lipidomics growth plans," said Matthew Lewis, Ph.D., Bruker Vice President, Metabolomics & Lipidomics. "By leveraging biocrates' expertise in quantitation and workflow automation, we accelerate the impact of MS-based omics to revolutionize and advance a shared multiomics vision."
Moritz Seuster, biocrates’ CEO, added: “Joining Bruker is a major milestone and a strong validation of our team’s hard work and vision. What makes this partnership so powerful is our shared passion for multiomics technologies and biocrates’ continued commitment to supporting and innovating across multiple MS technologies and vendors. With Bruker we’re poised to scale our impact while staying true to our mission to make omics quantitative, reproducible and easily accessible. We’re deeply thankful to our employees, customers, and partners who made this possible.”
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
JPK Instruments AG Strengthens Asian-Pacific Marketing Position
Labcyte Awarded 1st Patent in China
Targeted screening for C. difficile upon hospital admission could potentially identify most colonized patients
Change at the top of Analytik Jena - Ulrich Krauss charts new course
PerkinElmer Announces Leadership Succession Plan
Exercise training in ordinary people affects the activity of 500 genes
Pumping up the music of molecules - Significantly improving the "sense of smell" of molecular laser spectroscopy: Increases chances to reliably detect diseases
Oxford Instruments acquires Platinum Medical Imaging
